dirlotapide减少体重的评价client-owned狗在两个安慰剂对照临床研究在欧洲。

文章的细节

引用

复制到剪贴板

Gossellin J, McKelvie J, Sherington J,雷恩是的,Eagleson JS,罗文TG,桑德兰SJ

dirlotapide减少体重的评价client-owned狗在两个安慰剂对照临床研究在欧洲。

J兽医杂志。2007年8月,增刊1:73 30 - 80。

PubMed ID

17567517 (在PubMed

]

文摘

减肥的临床疗效和安全性的dirlotapide狗进行评估与并行设计两个进行的多中心研究。超重,不同品种的成年狗(n = 245)随机dirlotapide或安慰剂治疗在2:1的比例。Dirlotapide曾经口服每日对狗的初始剂量为0.05毫克/公斤/天开始在0天,14天后翻了一倍。每28天,狗被检查,体重,体况评分(BCS)记录,和剂量调整,以达到减肥目标。每个研究由三个连续的阶段:减肥(196天);weight-stabilization(84天);和后处理(28天)。预处理喂养和锻炼方案中继续治疗。Dirlotapide-treated狗显示平均体重15.9%(研究)和14.0%(研究B)年底减肥阶段(196天)。每周体重损失百分比dirlotapide明显大于安慰剂(P <或= 0.0002)。 Emesis and diarrhoea were experienced in both treatments but were more frequent with dirlotapide; resolution was spontaneous. BCS improved for 75.7-82.5% of dogs on dirlotapide treatment compared with 15.4-41.4% for placebo. Mean dirlotapide dosage at end of weight-loss phase was 0.38 (study A) and 0.29 (study B) mg/kg initial body weight/day. Dirlotapide was found to be clinically safe and effective in the reduction of body weight in overweight dogs.

DrugBank数据引用了这篇文章

药物

Dirlotapide